Johnson & Johnson (NYSE:JNJ) Holdings Lowered by Wedgewood Investors Inc. PA

Wedgewood Investors Inc. PA reduced its position in Johnson & Johnson (NYSE:JNJ) by 8.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 9,981 shares of the company’s stock after selling 900 shares during the period. Johnson & Johnson accounts for approximately 1.9% of Wedgewood Investors Inc. PA’s portfolio, making the stock its 9th largest holding. Wedgewood Investors Inc. PA’s holdings in Johnson & Johnson were worth $1,564,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. PYA Waltman Capital LLC grew its position in shares of Johnson & Johnson by 4.8% in the fourth quarter. PYA Waltman Capital LLC now owns 34,909 shares of the company’s stock valued at $5,472,000 after purchasing an additional 1,600 shares in the last quarter. Hexagon Capital Partners LLC grew its holdings in Johnson & Johnson by 24.5% during the 4th quarter. Hexagon Capital Partners LLC now owns 5,601 shares of the company’s stock valued at $878,000 after buying an additional 1,102 shares in the last quarter. Thompson Davis & CO. Inc. increased its position in shares of Johnson & Johnson by 9.9% during the fourth quarter. Thompson Davis & CO. Inc. now owns 2,789 shares of the company’s stock valued at $437,000 after buying an additional 251 shares during the period. Gibraltar Capital Management Inc. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $782,000. Finally, Bridgewater Advisors Inc. grew its stake in Johnson & Johnson by 2.4% during the fourth quarter. Bridgewater Advisors Inc. now owns 16,448 shares of the company’s stock valued at $2,578,000 after acquiring an additional 391 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada decreased their price target on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Finally, Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Trading Down 0.4 %

NYSE:JNJ opened at $149.27 on Monday. The company has a market cap of $359.25 billion, a PE ratio of 9.31, a price-to-earnings-growth ratio of 2.46 and a beta of 0.55. The company has a current ratio of 1.17, a quick ratio of 0.91 and a debt-to-equity ratio of 0.36. The company has a 50 day simple moving average of $154.19 and a two-hundred day simple moving average of $155.03. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the prior year, the firm earned $2.68 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.32%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 29.68%.

Insiders Place Their Bets

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.